Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes

被引:35
作者
Ariel, D. [1 ]
Kim, S. H. [1 ]
Abbasi, F. [1 ]
Lamendola, C. A. [1 ]
Liu, A. [1 ]
Reaven, G. M. [1 ]
机构
[1] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA
关键词
Prediabetes; Lipoprotein profile; Cardiovascular disease; Glucagon-like peptide-1 receptor agonist; Incretin treatment; CARDIOVASCULAR RISK; INSULIN-RESISTANCE; OBESITY; COMBINATION; CHOLESTEROL; METFORMIN; EFFICACY; SAFETY;
D O I
10.1016/j.numecd.2014.06.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: To evaluate the effects of 14 weeks of liraglutide plus modest caloric restriction on lipid/lipoprotein metabolism in overweight/obese persons with prediabetes. Methods and results: Volunteers with prediabetes followed a calorie-restricted diet (-500 Kcal/day) plus liraglutide (n = 23) or placebo (n = 27) for 14 weeks. The groups were similar in age (58 +/- 7 vs. 58 +/- 8 years) and body mass index (31.9 +/- 2.8 vs. 31.9 +/- 3.5 kg/m(2)). A comprehensive lipid/lipoprotein profile was obtained before and after intervention using vertical auto profile (VAP). Weight loss was greater in the liraglutide group than in the placebo group (6.9 vs. 3.3 kg, p < 0.001), as was the fall in fasting plasma glucose concentration (9.9 mg/dL vs. 0.3 mg/dL, p < 0.001). VAP analysis revealed multiple improvements in lipid/lipoprotein metabolism in liraglutide-treated compared with placebo-treated volunteers, including decreases in concentrations of total cholesterol, low-density lipoprotein cholesterol and several of its subclasses, triglyceride, and non-high-density cholesterol. The liraglutide-treated group also had a significant shift away from small, dense low-density lipoprotein-particles, as well as decreases in apolipoprotein B concentration and ratio of apolipoprotein B/apolipoprotein A-1. There were no significant changes in the lipoprotein profile in the placebo-treated group. Conclusion: Treatment with liraglutide plus modest calorie restriction led to enhanced weight loss, a decrease in fasting plasma glucose concentration, and improvement in multiple aspects of lipid/lipoprotein metabolism associated with increased cardiovascular disease (CVD) risk. The significant clinical benefit associated with liraglutide-assisted weight loss in a group at high risk for CVD - obese/overweight individuals with prediabetes e as seen in our pilot study, suggests that this approach deserves further study. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:1317 / 1322
页数:6
相关论文
共 17 条
[1]   Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects [J].
Abbasi, Fahim ;
Chen, Yii-Der Ida ;
Farin, Helke M. F. ;
Lamendola, Cindy ;
Reaven, Gerald M. .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (01) :64-69
[2]   Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].
Astrup, Arne ;
Rossner, Stephan ;
Van Gaal, Luc ;
Rissanen, Aila ;
Niskanen, Leo ;
Al Hakim, Mazin ;
Madsen, Jesper ;
Rasmussen, Mads F. ;
Lean, Michael E. J. .
LANCET, 2009, 374 (9701) :1606-1616
[3]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[4]   Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel [J].
Barter, PJ ;
Ballantyne, CM ;
Carmena, R ;
Cabezas, MC ;
Chapman, MJ ;
Couture, P ;
De Graaf, J ;
Durrington, PN ;
Faergeman, O ;
Frohlich, J ;
Furberg, CD ;
Gagne, C ;
Haffner, SM ;
Humphries, SE ;
Jungner, I ;
Krauss, RM ;
Kwiterovich, P ;
Marcovina, S ;
Packard, CJ ;
Pearson, TA ;
Reddy, KS ;
Rosenson, R ;
Sarrafzadegan, N ;
Sniderman, AD ;
Stalenhoef, AF ;
Stein, E ;
Talmud, PJ ;
Tonkin, AM ;
Walldius, G ;
Williams, KMS .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (03) :247-258
[5]   Cardiovascular risk factors attributable to obesity and overweight in Switzerland [J].
Davin, C. ;
Vollenweider, P. ;
Waeber, G. ;
Paccaud, F. ;
Marquese-Vidal, P. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2012, 22 (11) :952-958
[6]   Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [J].
Garber, Alan ;
Henry, Robert ;
Ratner, Robert ;
Garcia-Hernandez, Pedro A. ;
Rodriguez-Pattzi, Hiromi ;
Olvera-Alvarez, Israel ;
Hale, Paula M. ;
Zdravkovic, Milan ;
Bode, Bruce .
LANCET, 2009, 373 (9662) :473-481
[7]  
Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee
[8]   Cholesterol profile measurement by vertical auto profile method [J].
Kulkarni, Krishnaji R. .
CLINICS IN LABORATORY MEDICINE, 2006, 26 (04) :787-+
[9]   Atherogenic dyslipidemia in patients with established coronary artery disease [J].
Lahoz, C. ;
Mostaza, J. M. ;
Tranche, S. ;
Martin-Jadraque, R. ;
Mantilla, M. T. ;
Lopez-Rodriguez, I. ;
Monteiro, B. ;
Sanchez-Zamorano, M. A. ;
Taboada, M. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2012, 22 (02) :103-108
[10]   HOMEOSTASIS MODEL ASSESSMENT - INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA-GLUCOSE AND INSULIN CONCENTRATIONS IN MAN [J].
MATTHEWS, DR ;
HOSKER, JP ;
RUDENSKI, AS ;
NAYLOR, BA ;
TREACHER, DF ;
TURNER, RC .
DIABETOLOGIA, 1985, 28 (07) :412-419